Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a buy rating to a strong-buy rating in a research report released on Thursday morning.

Aurinia Pharmaceuticals Trading Down 2.0 %

Shares of Aurinia Pharmaceuticals stock opened at $8.29 on Thursday. Aurinia Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The company has a market capitalization of $1.14 billion, a P/E ratio of -55.26 and a beta of 1.26. The company has a fifty day moving average of $8.09 and a 200 day moving average of $8.04.

Insider Activity at Aurinia Pharmaceuticals

In other news, insider Greg Keenan sold 12,239 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $97,912.00. Following the sale, the insider now owns 161,789 shares in the company, valued at $1,294,312. This trade represents a 7.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Joseph M. Miller sold 61,859 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $494,872.00. Following the completion of the transaction, the chief financial officer now directly owns 633,515 shares in the company, valued at $5,068,120. This trade represents a 8.90 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 343,898 shares of company stock valued at $2,753,094. 4.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. SBI Securities Co. Ltd. purchased a new position in Aurinia Pharmaceuticals during the 4th quarter valued at approximately $25,000. GF Fund Management CO. LTD. bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at approximately $27,000. Tower Research Capital LLC TRC boosted its position in shares of Aurinia Pharmaceuticals by 368.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Aurinia Pharmaceuticals in the fourth quarter valued at $31,000. Finally, Natixis bought a new stake in Aurinia Pharmaceuticals in the fourth quarter worth $49,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.